Yan Dong1,2, Ying Cai3, Bo Liu4, Xiang Jiao1, Zhong-Tai Li1, Da-Yong Guo1, Xin-Wei Li1, Yong-Jun Wang1, Deng-Ke Yang1. 1. Department of Urology, 159th Hospital of PLA, Zhumadian, China. 2. Department of Oncology, Southwest Hospital, Third Military Medical University, Chongqing, China. 3. Institute of Toxicology, College of Preventive Medicine, Third Military Medical University, Chongqing, China. 4. Department of Burns & plastic Surgery, 159th Hospital of PLA, Zhumadian, China.
Abstract
AIM: To investigate the clinical relevance and functional role of HOXA13 in prostate cancer Methods: PCR, western blot and immunohistochemistry were performed to determine the expression. Kaplan-Meier and Cox regression survival analyses investigated the clinical relevance. Cell viability, flow cytometry and transwell assays were used to determine the functional roles. RESULTS: HOXA13 expression is sharply increased in carcinoma tissues and is significantly associated with poor prognosis of prostate cancer patients. Interestingly, nucleus not cytoplasm HOXA13 expression is associated with unfavorable survival of the patients. Furthermore, nucleus HOXA13 expression represents an unfavorable and independent prognosis factor of histological grade 2 or Gleason grade <8 patients. Functionally, forced expression of HOXA13 obviously promotes tumor cell proliferation, migration and invasion, whereas inhibits tumor cell apoptosis. CONCLUSION: HOXA13 is an unfavorable prognostic factor and a novel oncogene for prostate cancer.
AIM: To investigate the clinical relevance and functional role of HOXA13 in prostate cancer Methods: PCR, western blot and immunohistochemistry were performed to determine the expression. Kaplan-Meier and Cox regression survival analyses investigated the clinical relevance. Cell viability, flow cytometry and transwell assays were used to determine the functional roles. RESULTS:HOXA13 expression is sharply increased in carcinoma tissues and is significantly associated with poor prognosis of prostate cancerpatients. Interestingly, nucleus not cytoplasm HOXA13 expression is associated with unfavorable survival of the patients. Furthermore, nucleus HOXA13 expression represents an unfavorable and independent prognosis factor of histological grade 2 or Gleason grade <8 patients. Functionally, forced expression of HOXA13 obviously promotes tumor cell proliferation, migration and invasion, whereas inhibits tumor cell apoptosis. CONCLUSION:HOXA13 is an unfavorable prognostic factor and a novel oncogene for prostate cancer.
Entities:
Keywords:
HOXA13; oncogene; overall survival; prognostic factor; prostate cancer
Authors: Melissa S DeRycke; Melissa C Larson; Asha A Nair; Shannon K McDonnell; Amy J French; Lori S Tillmans; Shaun M Riska; Saurabh Baheti; Zachary C Fogarty; Nicholas B Larson; Daniel R O'Brien; John C Cheville; Liang Wang; Daniel J Schaid; Stephen N Thibodeau Journal: PLoS One Date: 2019-04-08 Impact factor: 3.240
Authors: Vincent T Janmaat; Kateryna Nesteruk; Manon C W Spaander; Auke P Verhaar; Bingting Yu; Rodrigo A Silva; Wayne A Phillips; Marcin Magierowski; Anouk van de Winkel; H Scott Stadler; Tatiana Sandoval-Guzmán; Luc J W van der Laan; Ernst J Kuipers; Ron Smits; Marco J Bruno; Gwenny M Fuhler; Nicholas J Clemons; Maikel P Peppelenbosch Journal: Nat Commun Date: 2021-06-07 Impact factor: 14.919